# Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML Patients

> **NCT02267993** · PHASE4 · COMPLETED · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 58 (actual)

## Conditions studied

- Thrombocytopenia

## Interventions

- **DRUG:** recombinant human thrombopoietin

## Key facts

- **NCT ID:** NCT02267993
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2018-08-01
- **Final completion:** 2018-08-31
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2025-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02267993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02267993, "Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02267993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*